Drugs / EC5026
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07694544 | Jul → Dec 2026 expected | chronic kidney disease | EicOsis Human Health Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06438471 | May 2026 → Dec 2027 expected | intervertebral disk degenerative disorder, neuropathy, painful, spinal cord injury, spinal stenosis +1 | EicOsis Human Health Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06089837 | Nov 2023 → Mar 2024 | — | EicOsis Human Health Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04908995 | Apr → May 2021 | — | EicOsis Human Health Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04228302 | Dec 2019 → Jul 2020 | — | EicOsis Human Health Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07142044 | Nov 2025 → Dec 2026 expected | Parkinson disease | EicOsis Human Health Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-31 | EicOsis Human Health Inc. | Results EicOsis Quarterly Newsletter January 2025 eicosis.com ↗
Across escalating dose regimens administered over a 7-day period, EC5026 was safe, well tolerated, and showed a favorable pharmacokinetic profile, paving the way for a convenient, once-daily dosing. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-12-31 | EicOsis Human Health Inc. | EicOsis Quarterly Newsletter January 2025 eicosis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EC5026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06438471 ↗ |
| Action | Inhibit | “EC5026 is an inhibitor of the soluble Epoxide Hydrolase (sEH) enzyme developed as a first-in-class analgesic for the treatment of pain.” NCT04228302 ↗ |
| Route | Oral | “single ascending oral doses of EC5026” NCT04228302 ↗ |